People with HIV who have moderate immune suppression appear to be at greater risk of severe COVID-19 'breakthrough' infection after vaccination, according to a new study. People with HIV who have ...

Results published Feb. 17, 2023, in Immunity have given a wider view of what happens in the earliest stages of HIV infection. Treatments against HIV prevent the replication of the virus, but do not ...

Drug conjugates (ADCs) developed at Institute of Science Tokyo combine a CD4 mimic with neutralizing antibodies for enhanced ...

Although HIV infection remains a global public health challenge, ART has transformed it from a fatal illness to a manageable lifetime condition for those who are successfully being treated.Initially, ...

Medicines that treat HIV are called antiretroviral therapy (ART). Genvoya is a combination tablet that contains the following four medicines that work together to treat HIV. Cobicistat is a “booster.” ...

A large international clinical trial has unveiled a promising new option for people living with highly treatment-resistant ...

To develop treatments that may one day entirely rid the body of HIV infection, scientists have long sought to identify all of the places that the virus can hide its genetic code. Now, in a study using ...

The global challenge posed by HIV-1 infection continues to drive research into its underlying mechanisms and the host immune response. Central to this pursuit is the role of T cells, particularly CD4 ...

In the early decades of the global response to HIV/AIDS, the focus was on saving lives. And rightly so: without antiretroviral treatment (ART), people lived less than a year, on average, from the time ...

In patients with HIV‑1 infection and virologic suppression, switching to an investigational regimen of doravirine plus ...

People with HIV who have moderate immune suppression appear to be at greater risk of severe COVID-19 “breakthrough” infection after vaccination, according to a study led by researchers at the Johns ...